The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma Meeting Abstract
| Authors: | Iyer, S.; Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; Kim, W. S.; Feldman, T.; Menne, T.; Belada, D.; Illès, A.; Tobinai, K.; Tsukasaki, K.; Yeh, S. P.; Shustov, A.; Hüttmann, A.; Savage, K. J.; Yuen, S.; Zinzani, P. L.; Miao, H.; Bunn, V.; Fenton, K.; Fanale, M.; Puhlmann, M.; Horwitz, S. |
| Abstract Title: | The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | t-cell lymphoma; chop; tcl; a plus chp; bv |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual event |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S411 |
| Language: | English |
| ACCESSION: | WOS:000691910500363 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(21)01925-X |
| Notes: | Meeting Abstract: TCL-150 -- Source: Wos |
